Advanced Catheter Therapies, Inc., a Chattanooga, TN-based research and development medical device company, completed its $4.5M Series B equity financing round.
TAM Ventures, Limited (TAMV), a subsidiary and a corporate venturing arm of Toray Industries, Inc. (TORAY) in Tokyo, Japan, made a strategic investment.
The company intends to use the funds to bring its OPC catheter to market for targeted applications.
Led by Paul J. Fitzpatrick, CEO, ACT has a portfolio of innovative catheter technologies addressing vascular disease and targeted endovascular drug delivery. The company recently received the first limited shipment of its lead product, the Occlusion Perfusion Catheter™ (OPC), a multi‐lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the targeted delivery of various therapeutic and diagnostic agents to the peripheral vasculature. The OPC, which is disease and agent agnostic, has the ability to create a localized treatment chamber and place the agent circumferentially into the vasculature of the treatment chamber. Inflow and outflow ports allow for chamber evacuation, filling and flushing.
It is patented and 510(k) cleared.
FinSMEs
17/03/2015